Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,913.50 -24.50 (-1.26%)

Bid:

1,913.00

Ask:

1,913.50

Spread: 0.50 (0.026%)

Market Cap: £76.74b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

GSK reports positive data, secures Shingrix presentation approval

(Alliance News) - GSK PLC on Wednesday reported positive developments with its shingles vaccine and its potential treatment for chronic hepatitis B, a...

GSK chronic hepatitis B treatment hits goal in two studies

(Sharecast News) - GSK on Wednesday said its potential chronic hepatitis B treatment had met primary endpoints in two trials that covered 1,800 patien...

LONDON MARKET CLOSE: Next impresses as FTSE 100 rockets to fresh high

(Alliance News) - Blue chips continued their strong start to the year on Tuesday with the FTSE 100 hitting a new record led by gains in retailer Next ...

GSK's Exdensur backed in Japan as asthma and rhinosinusitis treatment

(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and...

Japan approves GSK treatment for severe asthma

(Sharecast News) - GSK said Japan's Ministry of Health had approved its bronchial asthma treatment Exdensur after trial results showed "significant re...

GSK's Nucala backed in China for chronic obstructive pulmonary disease

(Alliance News) - GSK PLC on Monday said mepolizumab, sold under the brand name Nucala, has been approved in China for use in adults with chronic obst...

LONDON BRIEFING: Auction Technology rejects 11 FitzWalter buyout bids

(Alliance News) - Balfour Beatty sells ten UK assets for GBP87 million, Wizz Air and Ryanair report growth in passenger numbers for December, while Au...

GSK's COPD treatment approved by Chinese regulators

(Sharecast News) - Pharma giant GSK has received regulatory approval in China for its Nucala treatment for adults with inadequately controlled chronic...